Boston Scientific announced its Q3 2024 financial results, revealing a strong performance that exceeded market expectations. The company reported earnings per share (EPS) of $0.63, surpassing the forecast of $0.59. Revenue also beat projections, reaching $4.21 billion compared to the expected $4.04 billion. Following these results, Boston Scientific raised its annual earnings forecast, driven by robust demand for its cardiac implants. This positive outlook led to a 1.07% increase in the company's stock price in premarket trading. The company's market cap stands at $129.61 billion. However, the company also temporarily halted a pivotal heart equipment study due to unexpected events.